Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares

Published 26/07/2025, 21:00
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), a $2.06 billion market cap biotech company, sold 10,000 ordinary shares on July 25, 2025, for $155,598. The shares were sold at prices ranging from $15.315 to $15.67, close to the current trading price of $15.41. According to InvestingPro analysis, the stock appears overvalued at current levels.

According to a Form 4 filing with the Securities and Exchange Commission, Weinhoff also exercised options to acquire 10,000 ordinary shares at an exercise price of $3.85, for a total value of $38,500. The company maintains strong financial health with a current ratio of 14.37, indicating ample liquidity to meet short-term obligations.

Following the sale, Weinhoff directly owns 122,279 ordinary shares of Centessa Pharmaceuticals. The sale was executed under a Rule 10b5-1 trading plan adopted on May 22, 2024. Get access to more exclusive insider trading insights and 6 additional ProTips with an InvestingPro subscription.

In other recent news, Centessa Pharmaceuticals has been the focus of analyst attention and executive changes. Truist Securities initiated coverage on Centessa Pharmaceuticals with a Buy rating and set a price target of $30.00, highlighting the potential of the company’s Orexin-2 receptor agonist, ORX750, which targets conditions like narcolepsy and idiopathic hypersomnia. Piper Sandler also maintained its Overweight rating on Centessa, with a price target of $38.00, following a discussion with a sleep medicine specialist about the ORX750 treatment’s potential. The firm expressed continued interest in Centessa, with key data from the Phase 2 CRYSTAL-1 study expected in 2025.

Additionally, Centessa Pharmaceuticals announced the appointment of Raphael Deferiere as the new Chief Accounting Officer, effective May 27, 2025. Deferiere, who has a significant background in accounting, previously worked as an Assurance Partner at Ernst & Young, LLP. These developments indicate a period of strategic focus for the company, with both executive appointments and analyst endorsements highlighting its ongoing initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.